Stem Cell Therapies in Clinical Trials: Progress and Challenges.

By A. Trounson, Courtney A. McDonald. Cell Stem Cell, 2015

1,307 citations recorded by the source corpus.

Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of conditions using a variety of stem cell types. To date, there have been few reports of safety issues arising from autologous or allogeneic transplants. Many cells administered show transient presence for a few days with trophic influences on immune or inflammatory responses. Limbal stem cells have been registered as a product for eye burns in Europe and mesenchymal stem cells have been approved for pediatric graft versus host disease in Canada and New Zealand. Many other applications are progressing in trials, some with early benefits to patients.

Subfields: Genetics, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/a3f286699b88718900331eb92f5bf9a110094bb2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Luo-Qi Zhou
2. Hang Zhang
3. Xiaoyi Pang
4. B. Conti
5. E. M. Tottoli
6. Yun-hui Chu
7. Man Chen
8. Sheng Yang

Citations in the corpus

• Skin Wound Healing Process and New Emerging Technologies for Skin Wound Care and Regeneration (2020, background): “Indeed, stem cell and gene therapies are often considered to be the future of medicine, but further studies are needed to broaden these types of strategies in common clinical practice [76,77].”
• Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions (2022, background): “Another potential treatment is cell therapy, which utilizes stem cells to differentiate.(332) However, therapeutic approach is quite limited, and more research are need to discover new potential therapeutic strategy for ischemic stroke.”